top of page
O projecto


TESA , in its English acronym, is a consortium project established in 2009 through the collaborative effort of research institutes in Southern Africa and Universities involved in Clinical Trials. It is a network composed of different African and European research centers that collaborate with different levels of development and specialization, but with a complementary Clinical Research scenario. The project was also created as a mechanism to foster research collaboration through investment efforts on a joint path to a stronger and more sustainable clinical research landscape.

The TESA network has an overall strategic orientation aimed at creating a framework for collaboration, capacity building and training among consortium members and promoting healthy empowerment and personalized healthcare across the African region.

The TESA network has a proven track record in EDCTP-led Research and Development programs which have been established over the past decade among African and European countries that have participated since the first EDCTP programme.

Currently, the TESA project is in phase III in terms of implementation of the program financed by the EDCP, the former -

The effectiveness of IPTi has been demonstrated in several previous clinical trials which have shown that it is possible to reduce malaria by 30%, hospital admissions by 23% and anemia by 21%. It is also cost-effective, as the drug used for IPTi (sulfadoxine-pyrimethamine, SP) is inexpensive and IPTi uses an existing distribution system, through the Expanded Vaccination Program (EPI). The World Health Organization (WHO) currently recommends that children be given 3 doses of IPTi in the first year of life, along with childhood vaccines, through EPI.


Parceiros do Projecto




bottom of page